Although approved last September in the European Union, the National Institute for Health and Care Excellence had refused to cover the drug at the company-dictated price, which resulted in patients paying out-of-pocket.
A skin cancer drug developed by GlaxoSmithKline will be available through the United Kingdom's National Health Service after the company agreed to a secret discount.
Tafinlar, which fights melanoma, has won the green light from the National Institute for Health and Care Excellence (NICE), provided GSK supplies it at an undisclosed discount to the £1,400-per-week list price.
The drug has been approved for use in the European Union since September 2013, but once it has received final NICE approval, patients will not need to pay out of pocket to use it.
NICE said it had fast-tracked its recommendation for Tafinlar to the final draft stage in order to accelerate access to the treatment.
Link to the article: http://bit.ly/1p2mXwy
Source: The Telegraph
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More